Predicting the Effects of Blood Pressure-Lowering Treatment on Major Cardiovascular Events for Individual Patients With Type 2 Diabetes Mellitus: Results From Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation [Clinical Trials]

In conclusion, a multivariable treatment algorithm can identify those individuals who benefit most from blood pressure–lowering therapy in terms of ARR of major adverse cardiovascular events and may be used to guide treatment decisions in individual patients with diabetes. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00145925.

http://hyper.ahajournals.org/cgi/content/short/65/1/115?rss=1

Source: Hypertension - December 10, 2014 Category: Cardiology Authors: van der Leeuw, J., Visseren, F. L. J., Woodward, M., Zoungas, S., Kengne, A. P., van der Graaf, Y., Glasziou, P., Hamet, P., MacMahon, S., Poulter, N., Grobbee, D. E., Chalmers, J. Tags: Cardiovascular Pharmacology, Type 2 diabetes Clinical Trials Source Type: research